Navigation Links
Reportlinker Adds Gene Therapy - Worldwide Market Challenges & Opportunities
Date:11/30/2009

NEW YORK, Nov. 30 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Gene Therapy - Worldwide Market Challenges & Opportunities

http://www.reportlinker.com/p0164218/Gene-Therapy---Worldwide-Market-Challenges--Opportunities.html

Gene therapy promises to be one of the most important frontiers in medicine. Although no significant achievements for curing disease have been achieved, the future seems to hold significant potential in terms of developing such approaches. Advancements in gene therapy have provided useful data, which has helped in understanding the pathogenesis of diseases. The discipline heralds a significant potential for the biotechnology industry over the very long term, as the approach moves from research labs to clinical trials. Proteins and monoclonal antibodies have revolutionized the treatment of a wide variety of diseases, and gene-based therapies that deliver the DNA sequences encoding proteins and antibodies signify the next big step in the evolution of biopharmaceuticals. Gene therapy market is still in the experimental stages with success yet to be achieved in developing completely curative therapeutic drugs.

These and other market data and trends are presented in "Gene Therapy: Worldwide Market Challenges & Opportunities" by BizAcumen, Inc. Our reports are designed to be most comprehensive in geographic coverage and vertical market analyses.

GENE THERAPY BMR-1018

CONTENTS

1. METHODOLOGY 1

Study Reliability and Reporting Limitations 1

Disclaimers 2

Quantitative Techniques & Reporting Level 3

2. MARKET DYNAMICS 3

Future - On a Promising Note 3

Market Predictions Thrive On 4

China - First to Hit the Market 4

Counting on the Success Factors 4

Global Market Analysis 4

3. KEY ISSUES/TRENDS 5

Factors Influencing Gene Therapy Future Development 5

Human Genome Analysis 5

Gene Therapy - The Next Generation Cardiovascular Therapy 5

Public Support for Gene Therapy 6

RNAi Bode Bright Prospects 6

Factors Hampering Market Growth 6

Stringent Regulatory Laws in US and Europe Prolongs Gene

Therapy Development 6

Identifying Genetic Fault 6

Immune Response 6

Delivering Genetic Materials into Patient Cells 7

Multigene Disorders 7

Side Effects 7

Push Towards Germline Gene Transfer 8

Technical Limitations 8

4. THE GLOBAL LANDSCAPE 8

Alliances and Acquisitions - Strategy to Success 9

Patent Pooling: Yet Another Obstacle 9

Commercialization: A Road Uphill 9

Time Line in Gene Therapy Drug Development 10

Target Diseases and Players Involved 10

Key Players by Application Area 11

Various Gene Therapy Products Under Development (2007) 13

Gene Therapy Industry in Europe and the US - A Comparison 14

5. REVIEW OF MAJOR MARKETS 14

United States 14

Regulatory Environment 15

Food and Drug Administration 15

FDA Requires Additional Toxicology and Biodistribution Studies 15

IRB and IBC 16

Europe 16

Germany and UK- The Hub of European Gene Therapy Market 16

Regulatory Environment 17

Gene Therapy Advisory Committee 17

European Society of Gene and Cell Therapy (ESGCT) 18

Study of Regulatory Environment in Select European Countries 18

United Kingdom 18

Medicines and Healthcare Products Regulatory Agency 18

Germany 19

Italy 19

Sweden 19

The Netherlands 19

Switzerland 19

Japan 19

Asia-Pacific 20

World's First Gene Therapy Medicine Approved in China 20

Prospects for Gendicine 20

Competition 21

Gene Therapy Formulations under Clinical Trials by Select

Company in China 21

Rest of World 21

6. PRODUCT FACTS 21

Vector 22

Gene Cassette 22

Target cells 22

7. GENE THERAPY FOR DISEASE TREATMENT 22

Gene Therapy for Cancer Treatment 22

Gene Transfer and Gene Therapeutic Concepts in Cancer 23

Competitive Landscape in Cancer Gene Therapy 24

Gene Therapy Mechanism in Cancer 24

Advantages Over Chemotherapy 24

Developments in Cancer Gene Therapy 24

P53 Gene Therapy - A Novel Approach in Cancer Treatment 25

Gendicine - From Concept to Reality 26

Vaccines 26

Gene Therapy for Cardiovascular Disease 26

Cardiovascular Gene Therapy Products under Trial 27

Gene Therapy for Cystic Fibrosis Disease 27

Gene Therapy for Haemophilia B 28

Gene Therapy for AIDS/HIV 28

Gene Therapy for Parkinson's Disease 29

The Disease 29

Therapy 29

8. REGULATORY ENVIRONMENT 30

Gene therapy and Regulatory Environment 30

Gene Patents - An Overview 30

9. CORPORATE DEVELOPMENTS 31

International Consolidated to Acquire China Gene 31

Ark Therapeutics to Acquire Lymphatix 31

Oxford BioMedica Obtains Rights for RNAi Technology 32

Gene Bridges Inks Licensing Agreement with Genencor 32

AMT Enters into R&D Agreement with NIH 32

VGX Inks Supply Agreement with a U.K. Consortium 33

Researchers Develop Synthetic Gene Vectors to Reduce Body

Immune Responses 33

Cardium Therapeutics Receives Fast Track Designation for

Generx(TM) 34

Oxford Biomedica's ProSavin Enters Phase I/II Trial 34

Lentigen Acquires Gene Delivery Technology from Cell Genesys 34

VIRxSYS Acquires SMaRT(TM) RNA Technology 35

Gene Logic Divests Genomics Assets 35

Genzyme Inks Agreement with Ceregene 35

Silence Therapeutics Extends Agreement with Quark 35

Benda Inks HIV Vaccine Joint Venture with DNAVEC 36

Research Dynamics Bags Contract for Multicenter Clinical Study 36

Thermo Fischer Collaborates with Lentigen to Develop Gene-

Silencing Technology 36

Fovea Enters into Collaboration with GENZYME Corporation 37

Oxford BioMedica Inks Licensing Agreement with Children's

Hospital 37

Sigma and Oxford Sign Joint License Agreement for LentiVector

Technology 37

Benda Attains Additional Stake in SiBiono 37

Oxford BioMedica Acquires Oxxon 37

Oxford BioMedica and Sanofi-Aventis Agrees to Co-Develop and

Market TroVax 38

Illumina Completes Acquisition of Solexa 38

Illumina Brings Digital Gene Expression Applications 38

MolMed Develops Gene Therapy Based Treatment for Skin Cancer 39

Santaris Pharma Develops New Therapy to Lower Cholesterol Level 39

Researchers Develop Gene Therapy for Severe Burns 39

10. MAJOR PLAYERS 40

AnGes MG, Inc. (Japan) 40

Cell Genesys (US) 40

GenVec (US) 40

Genzyme Corporation (US) 40

Introgen Therapeutics, Inc. (US) 40

Oxford BioMedica (UK) 40

Shenzhen SiBiono GeneTech Co., Ltd (China) 40

Targeted Genetics Corp. (US) 41

Transgene (France) 41

Urigen Pharmaceuticals, Inc. (US) 41

Vical, Inc. (US) 41

EXHIBITS

Table 1: Global Gene Therapy Market for the Period 2007-2015

(Sales in US$ Million)

Table 2: Percentage Breakdown of Gene Therapy Clinical Trails

by Disease/Application Area in the World - 2007

Table 3: Percentage Breakdown of Gene Therapy Clinical Trials

by Gene Type Transferred in the World - 2007

Table 4: Percentage Breakdown of Gene Therapy Clinical Trials

by Vector Type in the World - 2007

Table 5: Gene Therapy Clinical Trials by Development Phase in

the World - 2007

Table 6: Percentage Breakdown of Gene Therapy Clinical Trials

by Geographic Region - 2007

Table 7: Percentage Breakdown Gene Therapy Clinical Trials by

Country in Europe - 2007

COMPANIES PROFILED

To order this report:

Genomics Industry: Gene Therapy - Worldwide Market Challenges & Opportunities

More Market Research Report


Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reportlinker Adds The Market for Anti-ageing Foods (2nd Edition)
2. Reportlinker Adds Childrens Food and Drinks in Europe - A Guide to Markets, Products and Innovation 2nd Edition
3. Reportlinker Adds Hand Sanitizers - US Market Trends
4. Reportlinker Adds Oncology Roadmap: Brand Spending Benchmarks and Market Forecast to 2013
5. Reportlinker Adds Imaging Agents - A Worldwide Market Review
6. Reportlinker Adds Toothpaste - Global Market Trends
7. Reportlinker Adds Cosmetic Surgery Procedures and Products - A US and European Market Review
8. Reportlinker Adds Organ and Tissue Transplantation - A World Market Analysis
9. Reportlinker Adds Central Nervous System Insomnia or Sleep Disorders
10. Reportlinker Adds North America Negative Pressure Wound Therapy (NPWT) Market: Strategic Market Analysis and Insight to 2012
11. Reportlinker Adds Infections Throat Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... ... , ... After years as an active staff surgeon and having served as ... Wayne Carman transitioned to chief of the Division of Plastic Surgery at what is ... chief and began a second three-year term in January of 2016. , The original ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... Georgia (PRWEB) , ... February 05, 2016 , ... Dr. ... to announce their 2nd Annual No Cost Dental Day to individuals in need. The ... The purpose of this No Cost Dental Day is to provide dental care to ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a topic that should ... event they are experiencing an illness. Migraines are a severe form of a headache ... migraines would not wish the pain on their worst enemy, the feeling can last ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Aralez Pharmaceuticals Inc. ... of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") ... and shareholders of Tribute. The combined company will operate ... company with operations in Canada , ... United States . Under the terms of the ...
(Date:2/5/2016)... February 5, 2016 --> ... report states that the global active pharmaceuticals ingredients (APIs) ... predicted to reach US$185.9 bn by 2020. It is ... 2014 to 2020. The title of the report is ... by Geography, and by Therapeutic Area) - Global Industry ...
(Date:2/5/2016)... Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: HSIC ... and services to office-based dental, animal health and medical ... agreement to acquire a majority ownership interest in Dental ... in Brazil . ... Dental Cremer is the dental distribution business of Cremer ...
Breaking Medicine Technology: